British Journal of Dermatology

<jats:title>Abstract</jats:title>
               <jats:sec>
                  <jats:title>Background</jats:title>
                  <jats:p>Recessive dystrophic epidermolysis bullosa (RDEB) is an epithelial fragility disease primarily affecting the skin and is caused by variants in the COL7A1 gene. Individuals with RDEB are predisposed to develop highly aggressive cutaneous squamous cell carcinomas (SCCs) which are the most common cause of premature death. There is a lack of effective prevention or treatment options for patients with RDEB-SCC.</jats:p>
               </jats:sec>
               <jats:sec>
                  <jats:title>Objectives</jats:title>
                  <jats:p>To evaluate the antitumour activity and safety of the polo-like kinase-1 (PLK1) inhibitor, rigosertib, two investigator-initiated open-label, single-arm phase II studies were opened in Europe and the USA and enrolled five patients with RDEB diagnosed with locally advanced and/or metastatic SCCs whose disease had not previously responded successfully to standard care.</jats:p>
               </jats:sec>
               <jats:sec>
                  <jats:title>Methods</jats:title>
                  <jats:p>Using a common protocol, patients were offered either oral or intravenous (IV) administration of rigosertib with consultation from the treating physician. Patients were monitored with clinical photography, biopsy, positron emission tomography/computed tomography scans and quality of life (QoL) questionnaires over the 12-month duration of the trial. The pharmacokinetics of drug absorption was monitored in four patients.</jats:p>
               </jats:sec>
               <jats:sec>
                  <jats:title>Results</jats:title>
                  <jats:p>Antitumour efficacy with acceptable toxicity was seen in patients on IV or oral therapy and two patients had a complete response within 6 months of treatment. Their QoL was not negatively impacted by treatment and drug absorption exceeded that seen in previous patient populations presumably due to the relatively high dosing in a cohort of underweight patients.</jats:p>
               </jats:sec>
               <jats:sec>
                  <jats:title>Conclusions</jats:title>
                  <jats:p>These data identify rigosertib as a promising drug therapy for patients with RDEB-SCC where there is a substantial unmet need, absence of approved therapies and where tumours arise on a background of a unique fibrotic and inflammatory environment ­characterized by germline mutations in COL7A1 that promote the development of homogenous primary tumours with aberrant PLK1 ­activity.</jats:p>
                  <jats:p>An author video to accompany this article is available online.</jats:p>
               </jats:sec>

Debra International

DEBRA Austria

Debra of America

Cure EB

Digital

Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility

Br J Dermatol

Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa

Orphanet J Rare Dis

Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986–2006

J Am Acad Dermatol

Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study

Acta Derm Venereol

Surgical management and oncological follow-up of cutaneous squamous cell carcinomas arising in epidermolysis bullosa patients

Int J Dermatol

The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: analysis of clinical outcomes and tumour characteristics in the Dutch EB Registry

APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa

Sci Transl Med

Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa

Cancer Res

Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa: best clinical practice guidelines

Variable outcome of immunotherapy in advanced multiple cutaneous squamous cell carcinomas in two patients with recessive dystrophic epidermolysis bullosa

PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma

N Engl J Med

A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa

Mapping the burden of severe forms of epidermolysis bullosa – implications for patient management

JAAD Int

ON01910, a non-ATP-competitive small molecule inhibitor of PLK1, is a potent anticancer agent

Cancer Cell

Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma

Clin Cancer Res

A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling

Cell

Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic ‘dual-hit’ option

Oncotarget

Therapeutic targeting PLK1 by ON-01910.Na is effective in local treatment of retinoblastoma

Oncol Res

Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand

The 2018 European Society of Cardiology/European Society of Hypertension and 2017 American College of Cardiology/American Heart Association blood pressure guidelines: more similar than different

JAMA

Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

Eur J Cancer

Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: an EB-specific quality of life instrument

Type VII collagen deficiency in the oncogenesis of cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa

J Invest Dermatol

Immune disregulation in cutaneous squamous cell carcinoma of patients with recessive dystrophic epidermolysis bullosa: a single pilot study

Life (Basel)

Characteristics and outcomes of squamous cell carcinoma and other cutaneous malignancies in epidermolysis bullosa: a systematic review

Adv Skin Wound Care

Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa

BMJ Case Rep

Induced remission of metastatic squamous cell carcinoma with an immune checkpoint inhibitor in a patient with recessive dystrophic epidermolysis bullosa

Case Rep Oncol

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3 K and PLK1 pathways, in adult patients with advanced solid malignancies

Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer

Am J Cancer Res

Management of squamous cell carcinoma in a patient with recessive-type epidermolysis bullosa dystrophica

Dermatol Surg

Significance of sentinel node biopsy in the management of squamous cell carcinoma arising from recessive dystrophic epidermolysis bullosa

J Dermatol

PET/CT in the thorax: pitfalls

Radiol Clin North Am

Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography

J Nucl Med

Recessive dystrophic epidermolysis bullosa (RDEB) is an epithelial fragility disease primarily affecting the skin and caused by variants in the COL7A1 gene. Individuals with RDEB are predisposed to develop highly aggressive cutaneous squamous cell carcinomas (SCC) which represent the most common cause of premature death. There is a lack of effective prevention or treatment options for patients with RDEB-SCC.
To evaluate the anti-tumor activity and safety of the polo-like kinase-1 (PLK1) inhibitor, rigosertib, two investigator initiated open-label, single arm phase 2 studies were opened in Europe and the United States and enrolled five RDEB patients diagnosed with locally advanced and/or metastatic SCCs that had failed prior standard of care.
Using a common protocol, patients were offered either oral or intravenous administration of rigosertib with consultation from the treating physician. Patients were monitored with clinical photography, biopsy, PET-CT scans and quality of life questionnaires over the 12 months duration of the trial. Pharmacokinetics of drug absorption was monitored in 4 patients.
Patients on intravenous or oral therapy showed anti-tumor efficacy with acceptable toxicity and two patients had a complete response within six months of treatment. Quality of life was not negatively impacted by treatment and drug absorption exceeded previous patient populations presumably due to the relatively high dosing in an underweight patient cohort.
These data identify rigosertib as a promising drug therapy for RDEB-SCC where there is a substantial unmet need, absence of approved therapies and where tumors arise on the background of a unique fibrotic and inflammatory environment characterized by germline mutations in COL7A1 that promote development of homogenous primary tumors with aberrant PLK1 activity.

Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis Bullosa Associated Advanced/Metastatic Cutaneous Squamous Cell Carcinoma.

Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced/metastatic cutaneous squamous cell carcinoma

Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced/metastatic cutaneous squamous cell carcinoma

Clinical Summary

What was studied

Key findings

Study limitations

Clinical implications

Related Questions